Alphatec (NASDAQ:ATEC) Price Target Cut to $16.00 by Analysts at Canaccord Genuity Group

Posted by on Nov 2nd, 2026

Alphatec (NASDAQ:ATEC – Free Report) had its price target cut by Canaccord Genuity Group from $19.00 to $16.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the medical technology company’s stock.

Several other equities research analysts have also recently weighed in on ATEC. Wall Street Zen cut Alphatec from a “buy” rating to a “hold” rating in a report on Sunday, October 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Alphatec in a report on Friday. Wells Fargo & Company cut their price objective on Alphatec from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday. BMO Capital Markets cut Alphatec from an “outperform” rating to a “market perform” rating and set a $8.00 target price for the company. in a research note on Friday. Finally, Needham & Company LLC decreased their price target on shares of Alphatec from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday. Twelve equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.13.

Get Our Latest Stock Report on Alphatec

Alphatec Price Performance

Shares of NASDAQ:ATEC opened at $7.04 on Friday. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -12.80 and a beta of 0.88. Alphatec has a 1 year low of $6.81 and a 1 year high of $23.29. The business’s 50-day moving average is $10.14 and its 200-day moving average is $10.62.

Alphatec (NASDAQ:ATEC – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The medical technology company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Alphatec had a negative net margin of 10.35% and a negative return on equity of 6,752.24%. The company had revenue of $221.17 million for the quarter, compared to analyst estimates of $225.16 million. During the same quarter last year, the firm posted $0.03 EPS. Alphatec’s revenue for the quarter was up 12.6% on a year-over-year basis. Analysts anticipate that Alphatec will post -0.45 EPS for the current year.

Insider Activity

In related news, CEO Patrick Miles bought 115,000 shares of the stock in a transaction dated Thursday, September 10th. The shares were purchased at an average price of $8.81 per share, for a total transaction of $1,013,150.00. Following the completion of the purchase, the chief executive officer directly owned 5,893,551 shares of the company’s stock, valued at $51,922,184.31. This represents a 1.99% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Tyson Marshall sold 8,168 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total value of $78,821.20. Following the completion of the transaction, the general counsel owned 630,398 shares in the company, valued at approximately $6,083,340.70. This trade represents a 1.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 13.48% of the company’s stock.

Hedge Funds Weigh In On Alphatec

A number of hedge funds have recently modified their holdings of the business. Bank of America Corp DE lifted its position in Alphatec by 26.9% during the 1st quarter. Bank of America Corp DE now owns 2,560,971 shares of the medical technology company’s stock worth $27,863,000 after acquiring an additional 543,059 shares during the period. Emerald Advisers LLC lifted its stake in shares of Alphatec by 10.4% in the 1st quarter. Emerald Advisers LLC now owns 1,807,307 shares of the medical technology company’s stock valued at $19,664,000 after purchasing an additional 169,578 shares in the last quarter. Granite Investment Partners LLC grew its holdings in Alphatec by 4.7% during the 1st quarter. Granite Investment Partners LLC now owns 1,195,156 shares of the medical technology company’s stock valued at $13,003,000 after purchasing an additional 54,043 shares in the last quarter. Emerald Mutual Fund Advisers Trust grew its stake in Alphatec by 27.1% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 1,156,826 shares of the medical technology company’s stock worth $12,586,000 after purchasing an additional 246,773 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY bought a new position in Alphatec in the second quarter worth about $9,413,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

About Alphatec

(Get Free Report)

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.

Featured Stories

Analyst Recommendations for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.